Biocon Biologics & Glenmark

Biocon Biologics & Glenmark

by admin- Wednesday, May 27th, 2020 04:12:12 PM

Biocon Biologics receives DCGI approval for emergency use of CytoSorb
Biocon has introduced that its subsidiary Biocon Biologics has obtained the Drugs Controller General of India’s (DCGI) approval for an extracorporeal blood purification (EBP) device CytoSorb® to reduce pro-inflammatory cytokines levels in confirmed COVID-19 patients admitted to the in depth care unit (ICU) with confirmed or imminent breathing failure.

Biocon Biologics has been granted licence for emergency use of CytoSorb in public interest via the Indian fitness regulator to treat COVID-19 sufferers who are 18 years of age or older. The licence may be powerful till manage of the COVID-19 outbreak in the usa.

Glenmark Pharmaceuticals gets ANDA popularity of Chlorzoxazone Tablets
Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by means of the USA Food & Drug Administration (USFDA) for Chlorzoxazone Tablets USP,
375 mg and 750 mg. This marks Glenmark’s first ANDA approval out in their new North American production facility based in Monroe, North Carolina.

News Updates